Background Image
Menu

Latest News

Sight and Sound announces partnership with Speaksee

20 March 2024

Sight and Sound announces partnership with Speaksee

Sight and Sound has joined forces with Dutch technology company Speaksee to deliver cutting-edge solutions in the UK. Speaksee’s innovative technology allows for real-time transcription of conversations, making it easier for individuals with hearing loss to follow along and...

Oxford BioTherapeutics announces launch of enhanced discovery platform, OGAP®-Verify, at World ADC Conference 2024

7 March 2024

Oxford BioTherapeutics announces launch of enhanced discovery platform, OGAP®-Verify, at World ADC Conference 2024

• OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discovery … • OGAP-Verify is now more sensitive than Immunohistochemistry (IHC), measuring membrane proteins as low as 50...

Pill Connect announces its acceptance onto the leading CDMO’s smart packaging supply program

5 March 2024

Pill Connect announces its acceptance onto the leading CDMO’s smart packaging supply program

Pill Connect, the smart dosing device company, today announces its acceptance onto the leading CDMO’s (Contract development and manufacturing organization) smart packaging supply program. Following an intensive validation process, the device has passed the product qualification...

Maxwellia announces the launch of LoviTest™

21 February 2024

Maxwellia announces the launch of LoviTest™

Alderley Park, Cheshire, UK - February 21, 2024 - Maxwellia is delighted to announce the launch of LoviTest™, a convenient at-home STI testing service for chlamydia and gonorrhoea. LoviTest marks the latest addition to Maxwellia's direct-to-consumer (D2C) sexual health offering...

LoviOne® crowned winner of the Pharmacy Product of the Year - Consumers’ Choice 2024

20 February 2024

LoviOne® crowned winner of the Pharmacy Product of the Year - Consumers’ Choice 2024

LoviOne®, Maxwellia’s emergency contraceptive pill brand, has been crowned winner of the Pharmacy Product of the Year Consumers’ Choice 2024. The highly anticipated Pharmacy Product of the Year awards are voted on by independent pharmacies and their customers, allowing them to...

Innovation funding boost for blister prevention firm

14 February 2024

Innovation funding boost for blister prevention firm

The Wirral-based business behind PelliTec blister prevention technology has secured grant funding from Innovate UK. Building on the success of former  Innovate UK programmes, like Women in Innovation and Young Innovators, the innovation agency is awarding £6.2m to firms...

Oxford BioTherapeutics announces first patient dosed with lead candidate, OBT076, in Phase 1b trial in adenoid cystic carcinomas of the head and neck

18 January 2024

Oxford BioTherapeutics announces first patient dosed with lead candidate, OBT076, in Phase 1b trial in adenoid cystic carcinomas of the head and neck

OBT, in collaboration with GORTEC, is evaluating OBT076, an innovative Antibody Drug Conjugate (ADC) targeting CD205 receptor that is highly overexpressed in solid and liquid tumors … Oxford, UK, San Jose, Calif., 18 January 2024 - Oxford BioTherapeutics (‘OBT’), a clinical...

Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia

8 January 2024

Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia

Manchester, UK, January 4, 2024 – Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent...

Oxford BioTherapeutics announces partner Boehringer Ingelheim received U.S. FDA Fast Track Designation for BI 764532 for potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of the lung

30 November 2023

Oxford BioTherapeutics announces partner Boehringer Ingelheim received U.S. FDA Fast Track Designation for BI 764532 for potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of the lung

• BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein  … • DLL3 antigen was discovered using OBT’s proprietary OGAP® drug discovery platform  … • This is the third Fast Track designation for BI 764532   … Oxford...

Blueberry Therapeutics meets primary and secondary endpoints in Phase 2b trial in onychomycosis

13 November 2023

Blueberry Therapeutics meets primary and secondary endpoints in Phase 2b trial in onychomycosis

Blueberry Therapeutics Limited (“Blueberry” or “the Company”), a pharmaceutical company focused on developing innovative, topical nanomedicines to treat dermatological conditions, announces that BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint...